Imagine a medicine that stays asleep in your blood until a special laser light wakes it up exactly where a tumor is located. Once activated, it acts like a tiny switch that shuts off the blood supply to the cancer, starving it and causing it to shrink. This avoids the need for major surgery and keeps the surrounding healthy organs working.
UTUC patients often cannot undergo surgery due to age or renal failure, and chemotherapy is largely ineffective. This leads to high morbidity and extreme healthcare costs, including over €220,000 per patient in some cases.
A two-part oncology platform consisting of an inactive photosensitizer drug (Padeliporfin-dipotassium) and a proprietary laser/fiber delivery device.
If you are a drug developer dealing with the high toxicity of systemic chemotherapy — this project developed Padeliporfin-VTP that targets tumor blood vessels specifically. This reduces side effects and preserves organ function for patients.
If you are a device manufacturer dealing with the need for precise, non-thermal light delivery in surgery — this project developed a proprietary laser and fiber device. This allows for repeatable treatment in the same area without damaging healthy tissue.
If you are a clinic dealing with the high cost of inpatient care and surgical complications — this project developed a minimally invasive alternative to radical nephroureterectomy. This could reduce the excess costs of approximately €220,840 per patient associated with renal failure.
Current UTUC treatment protocols can lead to excess costs of approximately €220,840 per patient over five years, primarily due to end-stage renal failure following surgery.
The project aims to use the funding to scale production and achieve market penetration in a sector projected to reach €4.39B by 2032.
The project utilizes a proprietary solution consisting of the Padeliporfin-dipotassium drug and a proprietary laser and fiber device.
The project objective is to achieve regulatory approval, reaching TRL9.
The project is scheduled to run from 2024-12-01 to 2026-11-30.
The project is led by a single SME, IMPACT BIOTECH LTD from Israel. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and regulatory approval rather than basic research.
Contact IMPACT BIOTECH LTD in Israel
Contact us to explore licensing opportunities for Padeliporfin-VTP technology.
